A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive.

In the 1996 study involving 15 men, a combined regimen of cyproterone acetate (CPA) and testosterone enanthate (TE) was tested for its effectiveness as a male contraceptive. The study divided the men into three groups, with 10 receiving varying doses of CPA plus TE and 5 receiving TE alone for 16 weeks. All men in the CPA plus TE groups became azoospermic, while only 3 of the 5 in the TE alone group achieved azoospermia. The time to reach azoospermia was faster in the CPA groups. No significant changes in sexual function, aggressive behavior, mood states, or relationship satisfaction were observed, and no serious side effects necessitated withdrawal from the study. The study concluded that the combination of CPA and TE is highly effective in suppressing spermatogenesis and could be a promising reversible male contraceptive.